nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—Levothyroxine—hypothyroidism	0.127	0.28	CbGbCtD
Nefazodone—ABCB1—Liothyronine—hypothyroidism	0.127	0.28	CbGbCtD
Nefazodone—ABCB1—Liotrix—hypothyroidism	0.124	0.273	CbGbCtD
Nefazodone—CYP3A4—Levothyroxine—hypothyroidism	0.0761	0.168	CbGbCtD
Nefazodone—Muscle twitching—Liothyronine—hypothyroidism	0.0125	0.0328	CcSEcCtD
Nefazodone—Cardiac failure congestive—Liothyronine—hypothyroidism	0.00986	0.0258	CcSEcCtD
Nefazodone—HTR2A—cerebellar cortex—hypothyroidism	0.0098	0.0906	CbGeAlD
Nefazodone—Angina pectoris—Liothyronine—hypothyroidism	0.00753	0.0197	CcSEcCtD
Nefazodone—SLC6A3—nerve—hypothyroidism	0.00741	0.0685	CbGeAlD
Nefazodone—SLC6A2—nerve—hypothyroidism	0.00598	0.0553	CbGeAlD
Nefazodone—Hyperkinesia—Dextrothyroxine—hypothyroidism	0.00528	0.0138	CcSEcCtD
Nefazodone—Hyperkinesia—Levothyroxine—hypothyroidism	0.00528	0.0138	CcSEcCtD
Nefazodone—HTR2A—urine—hypothyroidism	0.00521	0.0482	CbGeAlD
Nefazodone—Cellulitis—Liotrix—hypothyroidism	0.00489	0.0128	CcSEcCtD
Nefazodone—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00484	0.0127	CcSEcCtD
Nefazodone—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00484	0.0127	CcSEcCtD
Nefazodone—Oliguria—Liotrix—hypothyroidism	0.00483	0.0126	CcSEcCtD
Nefazodone—CYP3A4—urine—hypothyroidism	0.00482	0.0446	CbGeAlD
Nefazodone—CYP2D6—urine—hypothyroidism	0.00475	0.0439	CbGeAlD
Nefazodone—Increased appetite—Dextrothyroxine—hypothyroidism	0.00467	0.0122	CcSEcCtD
Nefazodone—Increased appetite—Levothyroxine—hypothyroidism	0.00467	0.0122	CcSEcCtD
Nefazodone—Hypertension—Liothyronine—hypothyroidism	0.00465	0.0122	CcSEcCtD
Nefazodone—Muscle twitching—Liotrix—hypothyroidism	0.00453	0.0119	CcSEcCtD
Nefazodone—Hypoglycaemia—Levothyroxine—hypothyroidism	0.0045	0.0118	CcSEcCtD
Nefazodone—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.0045	0.0118	CcSEcCtD
Nefazodone—Affect lability—Levothyroxine—hypothyroidism	0.00432	0.0113	CcSEcCtD
Nefazodone—Affect lability—Dextrothyroxine—hypothyroidism	0.00432	0.0113	CcSEcCtD
Nefazodone—Tachycardia—Liothyronine—hypothyroidism	0.00429	0.0112	CcSEcCtD
Nefazodone—Mood swings—Levothyroxine—hypothyroidism	0.00416	0.0109	CcSEcCtD
Nefazodone—Mood swings—Dextrothyroxine—hypothyroidism	0.00416	0.0109	CcSEcCtD
Nefazodone—Hypotension—Liothyronine—hypothyroidism	0.00411	0.0108	CcSEcCtD
Nefazodone—Dehydration—Dextrothyroxine—hypothyroidism	0.00408	0.0107	CcSEcCtD
Nefazodone—Dehydration—Levothyroxine—hypothyroidism	0.00408	0.0107	CcSEcCtD
Nefazodone—Lightheadedness—Liotrix—hypothyroidism	0.00398	0.0104	CcSEcCtD
Nefazodone—Hyperkinesia—Liotrix—hypothyroidism	0.00388	0.0102	CcSEcCtD
Nefazodone—Dysphagia—Dextrothyroxine—hypothyroidism	0.00379	0.00994	CcSEcCtD
Nefazodone—Dysphagia—Levothyroxine—hypothyroidism	0.00379	0.00994	CcSEcCtD
Nefazodone—Angina pectoris—Dextrothyroxine—hypothyroidism	0.0037	0.00968	CcSEcCtD
Nefazodone—Angina pectoris—Levothyroxine—hypothyroidism	0.0037	0.00968	CcSEcCtD
Nefazodone—HTR2A—nerve—hypothyroidism	0.00359	0.0332	CbGeAlD
Nefazodone—Cardiac failure congestive—Liotrix—hypothyroidism	0.00356	0.00932	CcSEcCtD
Nefazodone—Body temperature increased—Liothyronine—hypothyroidism	0.00347	0.0091	CcSEcCtD
Nefazodone—Increased appetite—Liotrix—hypothyroidism	0.00344	0.009	CcSEcCtD
Nefazodone—Weight decreased—Dextrothyroxine—hypothyroidism	0.00343	0.00899	CcSEcCtD
Nefazodone—Weight decreased—Levothyroxine—hypothyroidism	0.00343	0.00899	CcSEcCtD
Nefazodone—Hypoglycaemia—Liotrix—hypothyroidism	0.00331	0.00866	CcSEcCtD
Nefazodone—Cerebrovascular accident—Liotrix—hypothyroidism	0.0033	0.00863	CcSEcCtD
Nefazodone—Sweating—Dextrothyroxine—hypothyroidism	0.00324	0.00849	CcSEcCtD
Nefazodone—Sweating—Levothyroxine—hypothyroidism	0.00324	0.00849	CcSEcCtD
Nefazodone—Affect lability—Liotrix—hypothyroidism	0.00318	0.00832	CcSEcCtD
Nefazodone—Mood swings—Liotrix—hypothyroidism	0.00306	0.00801	CcSEcCtD
Nefazodone—Dehydration—Liotrix—hypothyroidism	0.003	0.00786	CcSEcCtD
Nefazodone—Flushing—Dextrothyroxine—hypothyroidism	0.00282	0.00738	CcSEcCtD
Nefazodone—Flushing—Levothyroxine—hypothyroidism	0.00282	0.00738	CcSEcCtD
Nefazodone—Abdominal distension—Liotrix—hypothyroidism	0.00281	0.00736	CcSEcCtD
Nefazodone—Dysphagia—Liotrix—hypothyroidism	0.00279	0.00731	CcSEcCtD
Nefazodone—CYP3A7—liver—hypothyroidism	0.00273	0.0252	CbGeAlD
Nefazodone—Angina pectoris—Liotrix—hypothyroidism	0.00272	0.00712	CcSEcCtD
Nefazodone—Bronchitis—Liotrix—hypothyroidism	0.00268	0.00703	CcSEcCtD
Nefazodone—Alopecia—Levothyroxine—hypothyroidism	0.00268	0.00703	CcSEcCtD
Nefazodone—Alopecia—Dextrothyroxine—hypothyroidism	0.00268	0.00703	CcSEcCtD
Nefazodone—Weight decreased—Liotrix—hypothyroidism	0.00253	0.00661	CcSEcCtD
Nefazodone—Tremor—Levothyroxine—hypothyroidism	0.00248	0.00649	CcSEcCtD
Nefazodone—Tremor—Dextrothyroxine—hypothyroidism	0.00248	0.00649	CcSEcCtD
Nefazodone—Agitation—Dextrothyroxine—hypothyroidism	0.00243	0.00636	CcSEcCtD
Nefazodone—Agitation—Levothyroxine—hypothyroidism	0.00243	0.00636	CcSEcCtD
Nefazodone—Angioedema—Dextrothyroxine—hypothyroidism	0.00242	0.00633	CcSEcCtD
Nefazodone—Angioedema—Levothyroxine—hypothyroidism	0.00242	0.00633	CcSEcCtD
Nefazodone—Sweating—Liotrix—hypothyroidism	0.00239	0.00625	CcSEcCtD
Nefazodone—Palpitations—Levothyroxine—hypothyroidism	0.00234	0.00612	CcSEcCtD
Nefazodone—Palpitations—Dextrothyroxine—hypothyroidism	0.00234	0.00612	CcSEcCtD
Nefazodone—CYP3A7-CYP3A51P—liver—hypothyroidism	0.00232	0.0215	CbGeAlD
Nefazodone—Convulsion—Levothyroxine—hypothyroidism	0.00229	0.006	CcSEcCtD
Nefazodone—Convulsion—Dextrothyroxine—hypothyroidism	0.00229	0.006	CcSEcCtD
Nefazodone—Arthralgia—Dextrothyroxine—hypothyroidism	0.00225	0.00589	CcSEcCtD
Nefazodone—Arthralgia—Levothyroxine—hypothyroidism	0.00225	0.00589	CcSEcCtD
Nefazodone—Anxiety—Dextrothyroxine—hypothyroidism	0.00224	0.00587	CcSEcCtD
Nefazodone—Anxiety—Levothyroxine—hypothyroidism	0.00224	0.00587	CcSEcCtD
Nefazodone—Hypoaesthesia—Liotrix—hypothyroidism	0.00222	0.00582	CcSEcCtD
Nefazodone—Confusional state—Dextrothyroxine—hypothyroidism	0.00218	0.0057	CcSEcCtD
Nefazodone—Confusional state—Levothyroxine—hypothyroidism	0.00218	0.0057	CcSEcCtD
Nefazodone—Shock—Levothyroxine—hypothyroidism	0.00212	0.00556	CcSEcCtD
Nefazodone—Shock—Dextrothyroxine—hypothyroidism	0.00212	0.00556	CcSEcCtD
Nefazodone—HTR1A—cardiovascular system—hypothyroidism	0.00211	0.0195	CbGeAlD
Nefazodone—Tachycardia—Dextrothyroxine—hypothyroidism	0.00211	0.00551	CcSEcCtD
Nefazodone—Tachycardia—Levothyroxine—hypothyroidism	0.00211	0.00551	CcSEcCtD
Nefazodone—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00209	0.00546	CcSEcCtD
Nefazodone—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00209	0.00546	CcSEcCtD
Nefazodone—Flushing—Liotrix—hypothyroidism	0.00207	0.00543	CcSEcCtD
Nefazodone—ADRA1A—heart—hypothyroidism	0.00206	0.0191	CbGeAlD
Nefazodone—Alopecia—Liotrix—hypothyroidism	0.00197	0.00517	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00197	0.00515	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00197	0.00515	CcSEcCtD
Nefazodone—Insomnia—Levothyroxine—hypothyroidism	0.00195	0.00511	CcSEcCtD
Nefazodone—Insomnia—Dextrothyroxine—hypothyroidism	0.00195	0.00511	CcSEcCtD
Nefazodone—ADRA1A—cardiovascular system—hypothyroidism	0.00195	0.018	CbGeAlD
Nefazodone—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00192	0.00504	CcSEcCtD
Nefazodone—Dyspnoea—Levothyroxine—hypothyroidism	0.00192	0.00504	CcSEcCtD
Nefazodone—Flatulence—Liotrix—hypothyroidism	0.00192	0.00502	CcSEcCtD
Nefazodone—Dysgeusia—Liotrix—hypothyroidism	0.0019	0.00499	CcSEcCtD
Nefazodone—SLC6A2—gonad—hypothyroidism	0.0019	0.0176	CbGeAlD
Nefazodone—SLC6A4—blood—hypothyroidism	0.00188	0.0174	CbGeAlD
Nefazodone—Vision blurred—Liotrix—hypothyroidism	0.00183	0.0048	CcSEcCtD
Nefazodone—Tremor—Liotrix—hypothyroidism	0.00182	0.00477	CcSEcCtD
Nefazodone—Agitation—Liotrix—hypothyroidism	0.00179	0.00468	CcSEcCtD
Nefazodone—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00178	0.00466	CcSEcCtD
Nefazodone—Feeling abnormal—Levothyroxine—hypothyroidism	0.00178	0.00466	CcSEcCtD
Nefazodone—Angioedema—Liotrix—hypothyroidism	0.00178	0.00465	CcSEcCtD
Nefazodone—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00176	0.00462	CcSEcCtD
Nefazodone—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00176	0.00462	CcSEcCtD
Nefazodone—Syncope—Liotrix—hypothyroidism	0.00174	0.00457	CcSEcCtD
Nefazodone—Palpitations—Liotrix—hypothyroidism	0.00172	0.0045	CcSEcCtD
Nefazodone—Urticaria—Dextrothyroxine—hypothyroidism	0.00171	0.00449	CcSEcCtD
Nefazodone—Urticaria—Levothyroxine—hypothyroidism	0.00171	0.00449	CcSEcCtD
Nefazodone—Loss of consciousness—Liotrix—hypothyroidism	0.00171	0.00448	CcSEcCtD
Nefazodone—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00171	0.00447	CcSEcCtD
Nefazodone—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00171	0.00447	CcSEcCtD
Nefazodone—Abdominal pain—Levothyroxine—hypothyroidism	0.00171	0.00447	CcSEcCtD
Nefazodone—Body temperature increased—Levothyroxine—hypothyroidism	0.00171	0.00447	CcSEcCtD
Nefazodone—SLC6A3—testis—hypothyroidism	0.0017	0.0157	CbGeAlD
Nefazodone—Convulsion—Liotrix—hypothyroidism	0.00169	0.00441	CcSEcCtD
Nefazodone—Hypertension—Liotrix—hypothyroidism	0.00168	0.0044	CcSEcCtD
Nefazodone—HTR1A—adrenal gland—hypothyroidism	0.00167	0.0155	CbGeAlD
Nefazodone—SLC6A2—adrenal gland—hypothyroidism	0.00166	0.0153	CbGeAlD
Nefazodone—Chest pain—Liotrix—hypothyroidism	0.00166	0.00434	CcSEcCtD
Nefazodone—Arthralgia—Liotrix—hypothyroidism	0.00166	0.00434	CcSEcCtD
Nefazodone—Anxiety—Liotrix—hypothyroidism	0.00165	0.00432	CcSEcCtD
Nefazodone—Confusional state—Liotrix—hypothyroidism	0.0016	0.00419	CcSEcCtD
Nefazodone—Oedema—Liotrix—hypothyroidism	0.00159	0.00416	CcSEcCtD
Nefazodone—Anaphylactic shock—Liotrix—hypothyroidism	0.00159	0.00416	CcSEcCtD
Nefazodone—Infection—Liotrix—hypothyroidism	0.00158	0.00413	CcSEcCtD
Nefazodone—ADRA2A—heart—hypothyroidism	0.00157	0.0145	CbGeAlD
Nefazodone—SLC6A3—cerebellum—hypothyroidism	0.00157	0.0145	CbGeAlD
Nefazodone—Shock—Liotrix—hypothyroidism	0.00156	0.00409	CcSEcCtD
Nefazodone—Tachycardia—Liotrix—hypothyroidism	0.00155	0.00406	CcSEcCtD
Nefazodone—Asthenia—Levothyroxine—hypothyroidism	0.00155	0.00405	CcSEcCtD
Nefazodone—Asthenia—Dextrothyroxine—hypothyroidism	0.00155	0.00405	CcSEcCtD
Nefazodone—ADRA1A—adrenal gland—hypothyroidism	0.00154	0.0142	CbGeAlD
Nefazodone—ADRA1A—blood—hypothyroidism	0.00154	0.0142	CbGeAlD
Nefazodone—Hyperhidrosis—Liotrix—hypothyroidism	0.00153	0.00402	CcSEcCtD
Nefazodone—Pruritus—Dextrothyroxine—hypothyroidism	0.00153	0.004	CcSEcCtD
Nefazodone—Pruritus—Levothyroxine—hypothyroidism	0.00153	0.004	CcSEcCtD
Nefazodone—Anorexia—Liotrix—hypothyroidism	0.00151	0.00396	CcSEcCtD
Nefazodone—Hypotension—Liotrix—hypothyroidism	0.00148	0.00388	CcSEcCtD
Nefazodone—Diarrhoea—Levothyroxine—hypothyroidism	0.00148	0.00387	CcSEcCtD
Nefazodone—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00148	0.00387	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00145	0.00379	CcSEcCtD
Nefazodone—Insomnia—Liotrix—hypothyroidism	0.00144	0.00376	CcSEcCtD
Nefazodone—Paraesthesia—Liotrix—hypothyroidism	0.00143	0.00373	CcSEcCtD
Nefazodone—Dyspnoea—Liotrix—hypothyroidism	0.00142	0.00371	CcSEcCtD
Nefazodone—Decreased appetite—Liotrix—hypothyroidism	0.00138	0.00361	CcSEcCtD
Nefazodone—Vomiting—Levothyroxine—hypothyroidism	0.00137	0.00359	CcSEcCtD
Nefazodone—Vomiting—Dextrothyroxine—hypothyroidism	0.00137	0.00359	CcSEcCtD
Nefazodone—SLC6A2—testis—hypothyroidism	0.00137	0.0127	CbGeAlD
Nefazodone—Rash—Dextrothyroxine—hypothyroidism	0.00136	0.00356	CcSEcCtD
Nefazodone—Rash—Levothyroxine—hypothyroidism	0.00136	0.00356	CcSEcCtD
Nefazodone—Dermatitis—Dextrothyroxine—hypothyroidism	0.00136	0.00356	CcSEcCtD
Nefazodone—Dermatitis—Levothyroxine—hypothyroidism	0.00136	0.00356	CcSEcCtD
Nefazodone—Constipation—Liotrix—hypothyroidism	0.00136	0.00355	CcSEcCtD
Nefazodone—Headache—Levothyroxine—hypothyroidism	0.00135	0.00354	CcSEcCtD
Nefazodone—Headache—Dextrothyroxine—hypothyroidism	0.00135	0.00354	CcSEcCtD
Nefazodone—ADRA2A—gonad—hypothyroidism	0.00134	0.0124	CbGeAlD
Nefazodone—HTR2A—heart—hypothyroidism	0.00133	0.0123	CbGeAlD
Nefazodone—ADRA2A—pituitary gland—hypothyroidism	0.00131	0.0121	CbGeAlD
Nefazodone—Feeling abnormal—Liotrix—hypothyroidism	0.00131	0.00342	CcSEcCtD
Nefazodone—Gastrointestinal pain—Liotrix—hypothyroidism	0.0013	0.0034	CcSEcCtD
Nefazodone—Nausea—Dextrothyroxine—hypothyroidism	0.00128	0.00336	CcSEcCtD
Nefazodone—Nausea—Levothyroxine—hypothyroidism	0.00128	0.00336	CcSEcCtD
Nefazodone—HTR1A—cerebellum—hypothyroidism	0.00128	0.0118	CbGeAlD
Nefazodone—Urticaria—Liotrix—hypothyroidism	0.00126	0.0033	CcSEcCtD
Nefazodone—HTR2A—cardiovascular system—hypothyroidism	0.00126	0.0116	CbGeAlD
Nefazodone—Body temperature increased—Liotrix—hypothyroidism	0.00125	0.00329	CcSEcCtD
Nefazodone—Abdominal pain—Liotrix—hypothyroidism	0.00125	0.00329	CcSEcCtD
Nefazodone—CYP3A5—blood—hypothyroidism	0.00123	0.0114	CbGeAlD
Nefazodone—ADRA1A—liver—hypothyroidism	0.0012	0.0111	CbGeAlD
Nefazodone—ADRA1A—cerebellum—hypothyroidism	0.00118	0.0109	CbGeAlD
Nefazodone—ADRA2A—adrenal gland—hypothyroidism	0.00117	0.0108	CbGeAlD
Nefazodone—ADRA2A—blood—hypothyroidism	0.00117	0.0108	CbGeAlD
Nefazodone—Hypersensitivity—Liotrix—hypothyroidism	0.00117	0.00306	CcSEcCtD
Nefazodone—CYP3A5—female gonad—hypothyroidism	0.00115	0.0106	CbGeAlD
Nefazodone—HTR2A—gonad—hypothyroidism	0.00114	0.0106	CbGeAlD
Nefazodone—Asthenia—Liotrix—hypothyroidism	0.00114	0.00298	CcSEcCtD
Nefazodone—ADRA2A—thyroid gland—hypothyroidism	0.00113	0.0105	CbGeAlD
Nefazodone—Pruritus—Liotrix—hypothyroidism	0.00112	0.00294	CcSEcCtD
Nefazodone—HTR2A—pituitary gland—hypothyroidism	0.00112	0.0103	CbGeAlD
Nefazodone—ADRA2A—female gonad—hypothyroidism	0.00109	0.0101	CbGeAlD
Nefazodone—Diarrhoea—Liotrix—hypothyroidism	0.00109	0.00284	CcSEcCtD
Nefazodone—Dizziness—Liotrix—hypothyroidism	0.00105	0.00275	CcSEcCtD
Nefazodone—Vomiting—Liotrix—hypothyroidism	0.00101	0.00264	CcSEcCtD
Nefazodone—Rash—Liotrix—hypothyroidism	0.001	0.00262	CcSEcCtD
Nefazodone—Dermatitis—Liotrix—hypothyroidism	0.001	0.00262	CcSEcCtD
Nefazodone—HTR2A—adrenal gland—hypothyroidism	0.000996	0.00921	CbGeAlD
Nefazodone—HTR2A—blood—hypothyroidism	0.000996	0.00921	CbGeAlD
Nefazodone—Headache—Liotrix—hypothyroidism	0.000994	0.0026	CcSEcCtD
Nefazodone—ADRA2A—testis—hypothyroidism	0.000969	0.00896	CbGeAlD
Nefazodone—CYP3A5—liver—hypothyroidism	0.000961	0.00888	CbGeAlD
Nefazodone—Nausea—Liotrix—hypothyroidism	0.000943	0.00247	CcSEcCtD
Nefazodone—CYP3A4—blood—hypothyroidism	0.000922	0.00852	CbGeAlD
Nefazodone—CYP2D6—blood—hypothyroidism	0.000907	0.00839	CbGeAlD
Nefazodone—ABCB1—adrenal cortex—hypothyroidism	0.000904	0.00836	CbGeAlD
Nefazodone—ADRA2A—cerebellum—hypothyroidism	0.000895	0.00827	CbGeAlD
Nefazodone—ABCB1—heart—hypothyroidism	0.000875	0.00809	CbGeAlD
Nefazodone—CYP2D6—female gonad—hypothyroidism	0.000846	0.00782	CbGeAlD
Nefazodone—ABCB1—cardiovascular system—hypothyroidism	0.000825	0.00763	CbGeAlD
Nefazodone—HTR2A—testis—hypothyroidism	0.000824	0.00762	CbGeAlD
Nefazodone—HTR2A—liver—hypothyroidism	0.000779	0.0072	CbGeAlD
Nefazodone—HTR2A—cerebellum—hypothyroidism	0.000761	0.00703	CbGeAlD
Nefazodone—CYP2D6—testis—hypothyroidism	0.00075	0.00694	CbGeAlD
Nefazodone—ABCB1—gonad—hypothyroidism	0.000749	0.00692	CbGeAlD
Nefazodone—ABCB1—pituitary gland—hypothyroidism	0.000731	0.00676	CbGeAlD
Nefazodone—CYP3A4—liver—hypothyroidism	0.000721	0.00667	CbGeAlD
Nefazodone—CYP2D6—liver—hypothyroidism	0.000709	0.00656	CbGeAlD
Nefazodone—CYP2D6—cerebellum—hypothyroidism	0.000693	0.00641	CbGeAlD
Nefazodone—ABCB1—adrenal gland—hypothyroidism	0.000653	0.00603	CbGeAlD
Nefazodone—ABCB1—blood—hypothyroidism	0.000653	0.00603	CbGeAlD
Nefazodone—ABCB1—thyroid gland—hypothyroidism	0.00063	0.00582	CbGeAlD
Nefazodone—ABCB1—female gonad—hypothyroidism	0.000609	0.00563	CbGeAlD
Nefazodone—ABCB1—testis—hypothyroidism	0.00054	0.00499	CbGeAlD
Nefazodone—ABCB1—liver—hypothyroidism	0.00051	0.00472	CbGeAlD
Nefazodone—ABCB1—cerebellum—hypothyroidism	0.000499	0.00461	CbGeAlD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000167	0.00299	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000167	0.00299	CbGpPWpGaD
Nefazodone—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000166	0.00298	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—TRH—hypothyroidism	0.00016	0.00288	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000156	0.0028	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000155	0.00278	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000155	0.00278	CbGpPWpGaD
Nefazodone—HTR2A—G alpha (q) signalling events—AVP—hypothyroidism	0.000151	0.00272	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—TSHB—hypothyroidism	0.00015	0.00269	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—TSHR—hypothyroidism	0.00015	0.00269	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000149	0.00268	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—TSHB—hypothyroidism	0.000149	0.00268	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—TSHR—hypothyroidism	0.000149	0.00268	CbGpPWpGaD
Nefazodone—ADRA1A—G alpha (q) signalling events—AVP—hypothyroidism	0.000148	0.00266	CbGpPWpGaD
Nefazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000148	0.00266	CbGpPWpGaD
Nefazodone—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000147	0.00264	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—IYD—hypothyroidism	0.000146	0.00263	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—TRH—hypothyroidism	0.000145	0.00261	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—TSHB—hypothyroidism	0.000143	0.00257	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—TSHR—hypothyroidism	0.000143	0.00257	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—TRH—hypothyroidism	0.000142	0.00256	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000135	0.00243	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000133	0.00238	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—TRH—hypothyroidism	0.000132	0.00238	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—TSHB—hypothyroidism	0.00013	0.00233	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—TSHR—hypothyroidism	0.00013	0.00233	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—TSHB—hypothyroidism	0.000127	0.00228	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—TSHR—hypothyroidism	0.000127	0.00228	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000125	0.00225	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ATP5O—hypothyroidism	0.000124	0.00224	CbGpPWpGaD
Nefazodone—CYP3A7—Biological oxidations—POMC—hypothyroidism	0.000124	0.00223	CbGpPWpGaD
Nefazodone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.00012	0.00216	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000118	0.00212	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—TSHB—hypothyroidism	0.000118	0.00212	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—TSHR—hypothyroidism	0.000118	0.00212	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—TPO—hypothyroidism	0.000117	0.0021	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000116	0.00208	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000115	0.00207	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—IYD—hypothyroidism	0.000115	0.00207	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000111	0.00199	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000107	0.00193	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—IYD—hypothyroidism	0.000106	0.0019	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.0001	0.0018	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.82e-05	0.00176	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ATP5O—hypothyroidism	9.82e-05	0.00176	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	9.79e-05	0.00176	CbGpPWpGaD
Nefazodone—HTR1A—G alpha (i) signalling events—POMC—hypothyroidism	9.7e-05	0.00174	CbGpPWpGaD
Nefazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	9.68e-05	0.00174	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—TRH—hypothyroidism	9.51e-05	0.00171	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	9.5e-05	0.00171	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—TRH—hypothyroidism	9.46e-05	0.0017	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—SH2B3—hypothyroidism	9.39e-05	0.00169	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TPO—hypothyroidism	9.23e-05	0.00166	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.12e-05	0.00164	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—TRH—hypothyroidism	9.05e-05	0.00163	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ATP5O—hypothyroidism	8.99e-05	0.00162	CbGpPWpGaD
Nefazodone—CYP3A5—Biological oxidations—POMC—hypothyroidism	8.97e-05	0.00161	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—AVP—hypothyroidism	8.84e-05	0.00159	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—AVP—hypothyroidism	8.79e-05	0.00158	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TRH—hypothyroidism	8.63e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TRH—hypothyroidism	8.59e-05	0.00154	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—TSHB—hypothyroidism	8.47e-05	0.00152	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—TSHR—hypothyroidism	8.47e-05	0.00152	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TPO—hypothyroidism	8.46e-05	0.00152	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	8.44e-05	0.00152	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—TSHB—hypothyroidism	8.43e-05	0.00151	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—TSHR—hypothyroidism	8.43e-05	0.00151	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—AVP—hypothyroidism	8.42e-05	0.00151	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TRH—hypothyroidism	8.22e-05	0.00148	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—TRH—hypothyroidism	8.21e-05	0.00148	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—TSHB—hypothyroidism	8.07e-05	0.00145	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—TSHR—hypothyroidism	8.07e-05	0.00145	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—TRH—hypothyroidism	8.04e-05	0.00144	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—IYD—hypothyroidism	7.98e-05	0.00143	CbGpPWpGaD
Nefazodone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.85e-05	0.00141	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.71e-05	0.00139	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	7.7e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TSHB—hypothyroidism	7.69e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TSHR—hypothyroidism	7.69e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.67e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TSHR—hypothyroidism	7.65e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TSHB—hypothyroidism	7.65e-05	0.00138	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—AVP—hypothyroidism	7.63e-05	0.00137	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—POMC—hypothyroidism	7.62e-05	0.00137	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—IYD—hypothyroidism	7.52e-05	0.00135	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	7.48e-05	0.00134	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—AVP—hypothyroidism	7.47e-05	0.00134	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—TRH—hypothyroidism	7.47e-05	0.00134	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TRH—hypothyroidism	7.46e-05	0.00134	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.34e-05	0.00132	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TSHB—hypothyroidism	7.33e-05	0.00132	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TSHR—hypothyroidism	7.33e-05	0.00132	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—TSHB—hypothyroidism	7.32e-05	0.00132	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—TSHR—hypothyroidism	7.32e-05	0.00132	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TRH—hypothyroidism	7.3e-05	0.00131	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—TSHB—hypothyroidism	7.17e-05	0.00129	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—TSHR—hypothyroidism	7.17e-05	0.00129	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—AVP—hypothyroidism	6.95e-05	0.00125	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ATP5O—hypothyroidism	6.79e-05	0.00122	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TRH—hypothyroidism	6.78e-05	0.00122	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.66e-05	0.0012	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—TSHR—hypothyroidism	6.66e-05	0.0012	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—TSHB—hypothyroidism	6.66e-05	0.0012	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TSHB—hypothyroidism	6.65e-05	0.00119	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TSHR—hypothyroidism	6.65e-05	0.00119	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.52e-05	0.00117	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TSHB—hypothyroidism	6.51e-05	0.00117	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TSHR—hypothyroidism	6.51e-05	0.00117	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—VAV3—hypothyroidism	6.45e-05	0.00116	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ATP5O—hypothyroidism	6.4e-05	0.00115	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TPO—hypothyroidism	6.38e-05	0.00115	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—POMC—hypothyroidism	6.38e-05	0.00115	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.06e-05	0.00109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TSHR—hypothyroidism	6.05e-05	0.00109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TSHB—hypothyroidism	6.05e-05	0.00109	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPO—hypothyroidism	6.01e-05	0.00108	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	5.98e-05	0.00108	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CLTC—hypothyroidism	5.9e-05	0.00106	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—POMC—hypothyroidism	5.87e-05	0.00106	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CLTC—hypothyroidism	5.87e-05	0.00105	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—POMC—hypothyroidism	5.84e-05	0.00105	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CLTC—hypothyroidism	5.62e-05	0.00101	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—POMC—hypothyroidism	5.59e-05	0.001	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—TSHB—hypothyroidism	5.42e-05	0.000973	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—VAV3—hypothyroidism	5.18e-05	0.000931	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—VAV3—hypothyroidism	5.16e-05	0.000926	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TRH—hypothyroidism	5.1e-05	0.000916	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CLTC—hypothyroidism	5.1e-05	0.000916	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TRH—hypothyroidism	5.07e-05	0.000912	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—POMC—hypothyroidism	5.07e-05	0.000911	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AVP—hypothyroidism	4.99e-05	0.000897	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CLTC—hypothyroidism	4.99e-05	0.000897	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AVP—hypothyroidism	4.97e-05	0.000893	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—POMC—hypothyroidism	4.97e-05	0.000892	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—VAV3—hypothyroidism	4.94e-05	0.000887	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—IYD—hypothyroidism	4.92e-05	0.000884	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TRH—hypothyroidism	4.86e-05	0.000873	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3C2A—hypothyroidism	4.83e-05	0.000867	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AVP—hypothyroidism	4.76e-05	0.000854	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	4.72e-05	0.000848	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—VAV3—hypothyroidism	4.71e-05	0.000846	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—VAV3—hypothyroidism	4.68e-05	0.000841	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CLTC—hypothyroidism	4.64e-05	0.000833	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—POMC—hypothyroidism	4.62e-05	0.000829	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TSHR—hypothyroidism	4.55e-05	0.000817	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TSHB—hypothyroidism	4.55e-05	0.000817	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AVP—hypothyroidism	4.53e-05	0.000815	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TSHB—hypothyroidism	4.52e-05	0.000812	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TSHR—hypothyroidism	4.52e-05	0.000812	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AVP—hypothyroidism	4.51e-05	0.000811	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—VAV3—hypothyroidism	4.48e-05	0.000805	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—VAV3—hypothyroidism	4.48e-05	0.000805	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TRH—hypothyroidism	4.41e-05	0.000792	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—VAV3—hypothyroidism	4.38e-05	0.000788	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TSHB—hypothyroidism	4.33e-05	0.000778	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TSHR—hypothyroidism	4.33e-05	0.000778	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AVP—hypothyroidism	4.32e-05	0.000776	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AVP—hypothyroidism	4.31e-05	0.000775	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TRH—hypothyroidism	4.31e-05	0.000775	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—TSHB—hypothyroidism	4.27e-05	0.000768	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AVP—hypothyroidism	4.22e-05	0.000759	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ATP5O—hypothyroidism	4.18e-05	0.000751	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—POMC—hypothyroidism	4.17e-05	0.000749	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—VAV3—hypothyroidism	4.07e-05	0.000732	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—VAV3—hypothyroidism	4.07e-05	0.000731	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—SLC5A5—hypothyroidism	4.05e-05	0.000728	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SH2B3—hypothyroidism	4.05e-05	0.000728	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SH2B3—hypothyroidism	4.03e-05	0.000724	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TRH—hypothyroidism	4.01e-05	0.00072	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—VAV3—hypothyroidism	3.98e-05	0.000715	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IGF1—hypothyroidism	3.97e-05	0.000713	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPO—hypothyroidism	3.93e-05	0.000706	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TSHB—hypothyroidism	3.93e-05	0.000706	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TSHR—hypothyroidism	3.93e-05	0.000706	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AVP—hypothyroidism	3.92e-05	0.000705	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AVP—hypothyroidism	3.92e-05	0.000704	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TSHB—hypothyroidism	3.92e-05	0.000703	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SH2B3—hypothyroidism	3.86e-05	0.000693	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSHR—hypothyroidism	3.84e-05	0.000691	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TSHB—hypothyroidism	3.84e-05	0.000691	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AVP—hypothyroidism	3.84e-05	0.000689	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3C2A—hypothyroidism	3.81e-05	0.000684	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	3.72e-05	0.000668	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—VAV3—hypothyroidism	3.7e-05	0.000665	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSHB—hypothyroidism	3.57e-05	0.000642	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TSHR—hypothyroidism	3.57e-05	0.000642	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AVP—hypothyroidism	3.56e-05	0.00064	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SH2B3—hypothyroidism	3.5e-05	0.000629	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3C2A—hypothyroidism	3.49e-05	0.000627	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SH2B3—hypothyroidism	3.43e-05	0.000616	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—POMC—hypothyroidism	3.32e-05	0.000596	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—POMC—hypothyroidism	3.3e-05	0.000593	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SLC5A5—hypothyroidism	3.2e-05	0.000575	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SH2B3—hypothyroidism	3.18e-05	0.000572	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—POMC—hypothyroidism	3.16e-05	0.000568	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—POMC—hypothyroidism	3.01e-05	0.000541	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PRL—hypothyroidism	3.01e-05	0.00054	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—POMC—hypothyroidism	3e-05	0.000539	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PRL—hypothyroidism	2.99e-05	0.000537	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TSHB—hypothyroidism	2.95e-05	0.000531	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SLC5A5—hypothyroidism	2.93e-05	0.000527	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—POMC—hypothyroidism	2.87e-05	0.000516	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—POMC—hypothyroidism	2.87e-05	0.000515	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PRL—hypothyroidism	2.86e-05	0.000514	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—POMC—hypothyroidism	2.81e-05	0.000504	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TSHB—hypothyroidism	2.78e-05	0.0005	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VAV3—hypothyroidism	2.78e-05	0.0005	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VAV3—hypothyroidism	2.77e-05	0.000497	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AVP—hypothyroidism	2.68e-05	0.000481	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AVP—hypothyroidism	2.67e-05	0.000479	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VAV3—hypothyroidism	2.65e-05	0.000476	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3C2A—hypothyroidism	2.63e-05	0.000473	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—POMC—hypothyroidism	2.61e-05	0.000469	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—POMC—hypothyroidism	2.6e-05	0.000468	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRL—hypothyroidism	2.6e-05	0.000467	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AVP—hypothyroidism	2.55e-05	0.000458	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—POMC—hypothyroidism	2.55e-05	0.000458	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRL—hypothyroidism	2.54e-05	0.000457	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	2.48e-05	0.000446	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VAV3—hypothyroidism	2.4e-05	0.000432	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—POMC—hypothyroidism	2.37e-05	0.000426	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRL—hypothyroidism	2.36e-05	0.000424	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VAV3—hypothyroidism	2.35e-05	0.000423	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AVP—hypothyroidism	2.31e-05	0.000416	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AVP—hypothyroidism	2.27e-05	0.000407	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SLC5A5—hypothyroidism	2.21e-05	0.000397	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VAV3—hypothyroidism	2.19e-05	0.000393	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—POMC—hypothyroidism	2.12e-05	0.000381	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AVP—hypothyroidism	2.11e-05	0.000378	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SLC5A5—hypothyroidism	2.08e-05	0.000374	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TSHB—hypothyroidism	1.82e-05	0.000327	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—POMC—hypothyroidism	1.78e-05	0.00032	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—POMC—hypothyroidism	1.77e-05	0.000318	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—hypothyroidism	1.71e-05	0.000308	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—hypothyroidism	1.7e-05	0.000306	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—POMC—hypothyroidism	1.7e-05	0.000305	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—POMC—hypothyroidism	1.67e-05	0.000301	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—hypothyroidism	1.63e-05	0.000293	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	1.62e-05	0.000291	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—hypothyroidism	1.54e-05	0.000276	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—hypothyroidism	1.53e-05	0.000276	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—hypothyroidism	1.51e-05	0.000271	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—hypothyroidism	1.48e-05	0.000266	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—hypothyroidism	1.45e-05	0.00026	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—hypothyroidism	1.4e-05	0.000251	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—hypothyroidism	1.36e-05	0.000245	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—hypothyroidism	1.35e-05	0.000242	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—hypothyroidism	1.16e-05	0.000208	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—hypothyroidism	1.09e-05	0.000196	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—hypothyroidism	7.13e-06	0.000128	CbGpPWpGaD
